LIGAND PHARMACEUTICALS (LGND) Stock Institutional Trading Activity


LIGAND PHARMACEUTICALS (LGND) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q1 2026), investors with some of the largest reported share count changes include Sequoia Financial Advisors, Tweedy, Browne Co All Funds (US), and Renaissance Technologies LLC. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q2 2014Renaissance Technologies LLCBuy38,59438,594$2,404

Frequently asked questions about LGND activity

  • Which institutional owners are buying LGND?

    Institutional owners buying LGND include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in LGND activity?

    "Buy" means an investor increased their reported position in LGND compared to the prior reporting period. This reflects growing exposure to LIGAND PHARMACEUTICALS (LGND) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in LGND increasing?

    Institutional interest in LGND can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.